{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:48:51Z","timestamp":1790401731563,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jchf.2025.03.007","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:01:55Z","timestamp":1743638515000},"page":"102440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Finerenone and NYHA Functional Class in Heart Failure"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2866-9414","authenticated-orcid":false,"given":"John W.","family":"Ostrominski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-7882","authenticated-orcid":false,"given":"Michele","family":"Senni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Borentian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Rohwedder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lay-Flurrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Antonio","family":"Lavagnino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2025.03.007_bib1","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2025.03.007_bib2","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.03.007_bib3","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2025.03.007_bib4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/hrt.2006.089656","article-title":"Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure","volume":"93","author":"Raphael","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2025.03.007_bib5","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1161\/CIRCULATIONAHA.117.028002","article-title":"Physical activity and prognosis in the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist)","volume":"136","author":"Hegde","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2025.03.007_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014240","article-title":"Clinical implications of the New York Heart Association classification","volume":"8","author":"Caraballo","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jchf.2025.03.007_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.14319","article-title":"Comparison of patient self-reported health status with clinician-assigned New York Heart Association classification","volume":"3","author":"Tran","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jchf.2025.03.007_bib8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamacardio.2021.0372","article-title":"Comparison of New York Heart Association class and patient-reported outcomes for heart failure with reduced ejection fraction","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2025.03.007_bib9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/jamacardio.2022.4427","article-title":"Associations between New York Heart Association classification, objective measures, and long-term prognosis in mild heart failure: a secondary analysis of the PARADIGM-HF Trial","volume":"8","author":"Rohde","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2025.03.007_bib10","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1136\/heartjnl-2020-317984","article-title":"Revisiting heart failure assessment based on objective measures in NYHA functional classes I and II","volume":"107","author":"Blacher","year":"2021","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2025.03.007_bib11","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2025.03.007_bib12","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2025.03.007_bib13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2025.03.007_bib14","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2014.08.036","article-title":"Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction","volume":"64","author":"Mentz","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.03.007_bib15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","article-title":"Heart failure with mid-range or mildly reduced ejection fraction","volume":"19","author":"Savarese","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jchf.2025.03.007_bib16","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/ejhf.2652","article-title":"Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial","volume":"24","author":"Ostrominski","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2025.03.007_bib17","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2025.03.007_bib18","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF Trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2025.03.007_bib19","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial","volume":"26","author":"Solomon","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2025.03.007_bib20","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events","volume":"62","author":"Lin","year":"2000","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"10.1016\/j.jchf.2025.03.007_bib21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2025.03.007_bib22","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2025.03.007_bib23","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved Trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2025.03.007_bib24","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2025.03.007_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/CIRCULATIONAHA.124.072055","article-title":"Effects of the non-steroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure","volume":"151","author":"Vaduganathan","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2025.03.007_bib26","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.jacc.2019.03.464","article-title":"Reasons for lack of improvement in treatment with evidence-based therapies in heart failure","volume":"73","author":"Bozkurt","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925002422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925002422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T21:02:58Z","timestamp":1772139778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177925002422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2213177925002422"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2025.03.007","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Finerenone and NYHA Functional Class in Heart Failure","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2025.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102440"}}